Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Nivolumab

Stage Phase 2

Sponsor National Cancer Institute

Modality antibody

Class PD-1 antibody

Target PD-1 / PD-L1 (TEC-0014)

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/api/v2/studies?query.cond=glioma&query.term=IDH

ClinicalTrials.gov API v2: IDH-mutant glioma interventional records plus 34 individual records, retrieved 11.07.2026 (registry fields as entered by sponsors)

Brief source I16

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT03718767

Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator Phenotype

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT03718767

Registry NCT03718767

Phase Phase 2

Status Active, not recruiting

Enrollment 62

Start 2019-03-27

Primary completion 2024-11-05

Study completion 2026-11-30

Catalyst Primary completion. 11.05.2024. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.